Manuscripts and Publications

Filters: Keyword is Female  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Aaron KJ, Kempf M-C, Christenson RH, Wilson CM, Muntner P, Shrestha S.  2012.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.. J Acquir Immune Defic Syndr. 61(4):499-506.
Agwu AL, Bethel J, Hightow-Weidman LB, Sleasman JW, Wilson CM, Rudy B, Kapogiannis BG.  2012.  Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naïve behaviorally HIV-infected youth.. AIDS Patient Care STDS. 26(4):193-6.
Alexander AB, Ott MA, Lally MA, Sniecinski K, Baker A, Zimet GD.  2015.  Adolescent decision making about participation in a hypothetical HIV vaccine trial.. Vaccine. 33(11):1331-7.
Andrinopoulos K, Clum G, Murphy DA, Harper G, Perez L, Xu J, Cunningham S, Ellen JM.  2011.  Health related quality of life and psychosocial correlates among HIV-infected adolescent and young adult women in the US.. AIDS Educ Prev. 23(4):367-81.
Arayasirikul S, Wilson EC.  2019.  Spilling the T on Trans-Misogyny and Microaggressions: An Intersectional Oppression and Social Process Among Trans Women.. J Homosex. 66(10):1415-1438.
B
Baheti G, Kiser JJ, Havens PL, Fletcher CV.  2011.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.. Antimicrob Agents Chemother. 55(11):5294-9.
Bansal A, Gough E, Ritter D, Wilson C, Mulenga J, Allen S, Goepfert PA.  2006.  Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.. AIDS. 20(3):353-60.
Bansal A, Yue L, Conway J, Yusim K, Tang J, Kappes J, Kaslow RA, Wilson CM, Goepfert PA.  2007.  Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.. AIDS. 21(18):2387-97.
Barnes W, D'Angelo L, Yamazaki M, Belzer M, Schroeder S, Palmer-Castor J, Futterman D, Kapogiannis B, Muenz L, D Harris R et al..  2010.  Identification of HIV-infected 12- to 24-year-old men and women in 15 US cities through venue-based testing.. Arch Pediatr Adolesc Med. 164(3):273-6.
Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, Gaur AH, Clark LF.  2014.  The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial.. AIDS Behav. 18(4):686-96.
Belzer ME, MacDonell KKolmodin, Clark LF, Huang J, Olson J, Kahana SY, Naar S, Sarr M, Thornton S.  2015.  Acceptability and Feasibility of a Cell Phone Support Intervention for Youth Living with HIV with Nonadherence to Antiretroviral Therapy.. AIDS Patient Care STDS. 29(6):338-45.
Boone MR, Cherenack EM, Wilson PA.  2015.  Self-Efficacy for Sexual Risk Reduction and Partner HIV Status as Correlates of Sexual Risk Behavior Among HIV-Positive Adolescent Girls and Women.. AIDS Patient Care STDS. 29(6):346-53.
Boyer CB, Greenberg L, Chutuape K, Walker B, Monte D, Kirk J, Ellen JM.  2017.  Exchange of Sex for Drugs or Money in Adolescents and Young Adults: An Examination of Sociodemographic Factors, HIV-Related Risk, and Community Context.. J Community Health. 42(1):90-100.
Boyer CB, Rivera OJSantiago, Chiaramonte DM, Ellen JM.  2018.  Examination of Behavioral, Social, and Environmental Contextual Influences on Sexually Transmitted Infections in At Risk, Urban, Adolescents, and Young Adults.. Sex Transm Dis. 45(8):542-548.
Boyer CB, Robles-Schrader GM, Li SX, Miller RL, Korelitz J, Price GN, Torres CMRivera, Chutuape KS, Stines SJ, Straub DM et al..  2014.  A comparison of network-based strategies for screening at-risk Hispanic/Latino adolescents and young adults for undiagnosed asymptomatic HIV infection.. J Adolesc Health. 55(6):765-73.
Boyer CB, Hightow-Weidman L, Bethel J, Li SX, Henry-Reid L, Futterman D, Maturo D, Straub DM, Howell K, Reid S et al..  2013.  An assessment of the feasibility and acceptability of a friendship-based social network recruitment strategy to screen at-risk African American and Hispanic/Latina young women for HIV infection.. JAMA Pediatr. 167(3):289-96.
Brennan J, Kuhns LM, Johnson AK, Belzer M, Wilson EC, Garofalo R.  2012.  Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization.. Am J Public Health. 102(9):1751-7.
Brick LAnn D, Nugent NR, Kahana SY, Bruce D, Tanney MR, M Fernández I, Bauermeister JA.  2018.  Interaction Effects of Neighborhood Disadvantage and Individual Social Support on Frequency of Alcohol Use in Youth Living with HIV.. Am J Community Psychol. 61(3-4):276-284.
Brothers J, Hotton AL, Hosek SG, Harper GW, M Fernández I.  2016.  Young Women Living with HIV: Outcomes from a Targeted Secondary Prevention Empowerment Pilot Trial.. AIDS Patient Care STDS. 30(5):229-35.
Brothers J, Harper GW, M Fernández I, Hosek SG.  2014.  EVOLUTION--taking charge and growing stronger: the design, acceptability, and feasibility of a secondary prevention empowerment intervention for young women living with HIV.. AIDS Patient Care STDS. 28(1):33-42.
Brown LK, Whiteley L, Harper GW, Nichols S, Nieves A.  2015.  Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
Brown LK, Kennard BD, Emslie GJ, Mayes TL, Whiteley LB, Bethel J, Xu J, Thornton S, Tanney MR, Hawkins LA et al..  2016.  Effective Treatment of Depressive Disorders in Medical Clinics for Adolescents and Young Adults Living With HIV: A Controlled Trial.. J Acquir Immune Defic Syndr. 71(1):38-46.
Bruce D, Kahana SY, Bauermeister JA, Nichols SL, Hightow-Weidman LB, Heinze JE, Shea J, M Fernández I.  2015.  Neighborhood-level and individual-level correlates of cannabis use among young persons living with HIV/AIDS.. Drug Alcohol Depend. 151:173-80.
Bruce D, Harper GW, M Fernández I, Jamil OB.  2012.  Age-concordant and age-discordant sexual behavior among gay and bisexual male adolescents.. Arch Sex Behav. 41(2):441-8.
C
Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu C-S, McGowan I.  2012.  "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.. AIDS Behav. 16(7):1761-74.
Castillo M, Palmer BJ, Rudy BJ, Fernandez MIsabel.  2012.  Creating partnerships for HIV prevention among YMSM: the Connect Protect® Project and House and Ball Community in Philadelphia.. J Prev Interv Community. 40(2):165-75.
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
Chutuape KS, Willard N, Sanchez K, Straub DM, Ochoa TN, Howell K, Rivera C, Ramos I, Ellen JM.  2010.  Mobilizing communities around HIV prevention for youth: how three coalitions applied key strategies to bring about structural changes.. AIDS Educ Prev. 22(1):15-27.
Chutuape KS, Ziff M, Auerswald C, Castillo M, McFadden A, Ellen J.  2009.  Examining differences in types and location of recruitment venues for young males and females from urban neighborhoods: findings from a multi-site HIV prevention study.. J Urban Health. 86(1):31-42.
Clum GA, Chung S-E, Ellen JM, Perez LV, Murphy DA, Harper GW, Hamvas L.  2012.  Victimization and sexual risk behavior in young, HIV positive women: exploration of mediators.. AIDS Behav. 16(4):999-1010.
Clum GA, Andrinopoulos K, Muessig K, Ellen JM.  2009.  Child abuse in young, HIV-positive women: linkages to risk.. Qual Health Res. 19(12):1755-68.
Clum GA, Czaplicki L, Andrinopoulos K, Muessig K, Hamvas L, Ellen JM.  2013.  Strategies and outcomes of HIV status disclosure in HIV-positive young women with abuse histories.. AIDS Patient Care STDS. 27(3):191-200.
Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ.  2019.  Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.. J Int AIDS Soc. 22(2):e25252.
Cunningham CK, Rudy BJ, Xu J, Bethel J, Kapogiannis BG, Ahmad S, Wilson CM, Flynn PM.  2010.  Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States.. Pediatr Infect Dis J. 29(6):530-4.
D
Deeds BGriffin, Peralta L, Willard N, Ellen J, Straub DM, Castor J.  2008.  The role of community resource assessments in the development of 15 adolescent health community-researcher partnerships.. Prog Community Health Partnersh. 2(1):31-9.
Dempsey AG, Macdonell KE, Naar-King S, Lau C-Y.  2012.  Patterns of disclosure among youth who are HIV-positive: a multisite study.. J Adolesc Health. 50(3):315-7.
Dietz E, Clum GA, Chung S-E, Leonard L, Murphy DA, Perez LV, Harper GW, Ellen JM.  2010.  Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities.. J Adolesc Health. 46(3):278-83.
Dinaj-Koci V, Wang B, Naar-King S, MacDonell KKolmodin.  2019.  A Multi-Site Study of Social Cognitive Factors Related to Adherence Among Youth Living With HIV in the New Era of Antiretroviral Medication.. J Pediatr Psychol. 44(1):98-109.
M Dolcini M, Harper GW, Boyer CB, Pollack LM.  2010.  Project ORE: A friendship-based intervention to prevent HIV/STI in urban African American adolescent females.. Health Educ Behav. 37(1):115-32.
Dowshen N, Matone M, Luan X, Lee S, Belzer M, Fernandez MIsabel, Rubin D.  2016.  Behavioral and Health Outcomes for HIV+ Young Transgender Women (YTW) Linked To and Engaged in Medical Care.. LGBT Health. 3(2):162-7.
E
Ellen JM, Kapogiannis B, J Fortenberry D, Xu J, Willard N, Duval A, Pace J, Loeb J, Monte D, Bethel J.  2014.  HIV viral load levels and CD4+ cell counts of youth in 14 cities.. AIDS. 28(8):1213-9.
Ellen JM, Greenberg L, Willard N, Korelitz J, Kapogiannis BG, Monte D, Boyer CB, Harper GW, Henry-Reid LM, Friedman LB et al..  2015.  Evaluation of the effect of human immunodeficiency virus-related structural interventions: the connect to protect project.. JAMA Pediatr. 169(3):256-63.
Esposito-Smythers C, Brown LK, Wolff J, Xu J, Thornton S, Tidey J.  2014.  Substance abuse treatment for HIV infected young people: an open pilot trial.. J Subst Abuse Treat. 46(2):244-50.
F
M Fernández I, Huszti HC, Wilson PA, Kahana S, Nichols S, Gonin R, Xu J, Kapogiannis BG.  2015.  Profiles of Risk Among HIV-Infected Youth in Clinic Settings.. AIDS Behav. 19(5):918-30.
M Fernández I, Hosek S, Warren JC, Jacobs RJ, Hernandez N, Martinez J.  2011.  Development of an easy to use tool to assess HIV treatment readiness in adolescent clinical care settings.. AIDS Care. 23(11):1492-9.
Finger JL, Clum GA, Trent ME, Ellen JM.  2012.  Desire for pregnancy and risk behavior in young HIV-positive women.. AIDS Patient Care STDS. 26(3):173-80.
J Fortenberry D, Koenig LJ, Kapogiannis BG, Jeffries CL, Ellen JM, Wilson CM.  2017.  Implementation of an Integrated Approach to the National HIV/AIDS Strategy for Improving Human Immunodeficiency Virus Care for Youths.. JAMA Pediatr. 171(7):687-693.
G
Gamarel KE, Nichols S, Kahler CW, Westfall AO, Lally MA, Wilson CM.  2018.  A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIV.. Sex Transm Infect. 94(4):304-308.
Gamarel KE, Nelson KM, Heinze J, Chiaramonte DM, Miller RL.  2019.  The moderating role of resilience resources in the association between crime exposure and substance use among young sexual minority men.. Subst Use Misuse. 54(11):1787-1798.
Gamarel KE, Nelson KM, Brown L, M Fernández I, Nichols S.  2017.  The Usefulness of the CRAFFT in Screening for Problematic Drug and Alcohol Use Among Youth Living with HIV.. AIDS Behav. 21(7):1868-1877.
Gamarel KE, Westfall AO, Lally MA, Hosek S, Wilson CM.  2018.  Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
Gamarel KE, Brown L, Kahler CW, M Fernández I, Bruce D, Nichols S.  2016.  Prevalence and correlates of substance use among youth living with HIV in clinical settings.. Drug Alcohol Depend. 169:11-18.
Gamarel KE, Nelson KM, Stephenson R, Rivera OJSantiago, Chiaramonte D, Miller RLin.  2018.  Anticipated HIV Stigma and Delays in Regular HIV Testing Behaviors Among Sexually-Active Young Gay, Bisexual, and Other Men Who Have Sex with Men and Transgender Women.. AIDS Behav. 22(2):522-530.
Geanuracos CG, Cunningham SD, Weiss G, Forte D, Reid LMHenry, Ellen JM.  2007.  Use of geographic information systems for planning HIV prevention interventions for high-risk youths.. Am J Public Health. 97(11):1974-81.
Giguere R, Carballo-Diéguez A, Ventuneac A, Mabragaña M, Dolezal C, Chen BA, Kahn JA, Zimet GD, McGowan I.  2012.  Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.. Cult Health Sex. 14(2):151-66.
Gilbert ALewis, Knopf AS, J Fortenberry D, Hosek SG, Kapogiannis BG, Zimet GD.  2015.  Adolescent Self-Consent for Biomedical Human Immunodeficiency Virus Prevention Research.. J Adolesc Health. 57(1):113-9.
Gross IMoses, Hosek S, Richards MHeather, M Fernández I.  2016.  Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
H
Harper GW, Jadwin-Cakmak LA, Popoff E, Campbell BAnne, Granderson R, Wesp LM.  2019.  Transgender and Other Gender-Diverse Youth's Progression Through the HIV Continuum of Care: Socioecological System Barriers.. AIDS Patient Care STDS. 33(1):32-43.
Harper GW, Lemos D, Hosek SG.  2014.  Stigma reduction in adolescents and young adults newly diagnosed with HIV: findings from the Project ACCEPT intervention.. AIDS Patient Care STDS. 28(10):543-54.
Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, Lujan-Zilbermann J, Kapogiannis BG, Wilson CM, Stephensen CB.  2012.  Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.. J Clin Endocrinol Metab. 97(11):4004-13.
Havens PL, Hazra R.  2015.  Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.. Pediatr Infect Dis J. 34(4):406-8.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, D Harris R et al..  2018.  Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.. Clin Infect Dis. 66(2):220-228.
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
Hightow-Weidman L, Muessig K, Claude K, Roberts J, Zlotorzynska M, Sanchez T.  2020.  Maximizing Digital Interventions for Youth in the Midst of Covid-19: Lessons from the Adolescent Trials Network for HIV Interventions.. AIDS Behav. 24(8):2239-2243.
Horvath KJ, Lammert S, LeGrand S, Muessig KE, Bauermeister JA.  2017.  Using technology to assess and intervene with illicit drug-using persons at risk for HIV.. Curr Opin HIV AIDS. 12(5):458-466.
Hosek S, Brothers J, Lemos D.  2012.  What HIV-positive young women want from behavioral interventions: a qualitative approach.. AIDS Patient Care STDS. 26(5):291-7.
Hosek SG, Harper GW, Lemos D, Burke-Miller J, Lee S, Friedman L, Martinez J.  2018.  Project ACCEPT: Evaluation of a Group-Based Intervention to Improve Engagement in Care for Youth Newly Diagnosed with HIV.. AIDS Behav. 22(8):2650-2661.
Hosek SG, Lemos D, Harper GW, Telander K.  2011.  Evaluating the acceptability and feasibility of Project ACCEPT: an intervention for youth newly diagnosed with HIV.. AIDS Educ Prev. 23(2):128-44.
J
Jaspan HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker L-G, Wilson CM, Duerr A et al..  2008.  Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.. J Acquir Immune Defic Syndr. 47(1):86-92.
Jennings JM, Ellen JM, Deeds BGriffin, D Harris R, Muenz LR, Barnes W, Lee SS, Auerswald CL.  2009.  Youth living with HIV and partner-specific risk for the secondary transmission of HIV.. Sex Transm Dis. 36(7):439-44.
K
Kahana SY, Fernandez MIsabel, Wilson PA, Bauermeister JA, Lee S, Wilson CM, Hightow-Weidman LB.  2015.  Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.. J Acquir Immune Defic Syndr. 68(2):169-77.
Kahana SY, Jenkins RA, Bruce D, Fernandez MI, Hightow-Weidman LB, Bauermeister JA.  2016.  Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.. PLoS One. 11(4):e0151106.
Kahn JA, Rudy BJ, Xu J, Kapogiannis B, Secord E, Gillison M.  2016.  Prevalence and risk factors for oral DNA tumor viruses in HIV-infected youth.. J Med Virol. 88(11):1944-52.
Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.  2013.  Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.. Clin Infect Dis. 57(5):735-44.
Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K.  2012.  Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women.. J Adolesc Health. 50(5):464-70.
Kahn JA, Xu J, Kapogiannis BG, Sleasman JW.  2017.  Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay.. J Acquir Immune Defic Syndr. 75(2):241-245.
Kahn JA, Rudy BJ, Xu J, Secord EA, Kapogiannis BG, Thornton S, Gillison ML.  2015.  Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.. Sex Transm Dis. 42(5):246-52.
Kahn JA, Lee J, Belzer M, Palefsky JM.  2018.  HIV-Infected Young Men Demonstrate Appropriate Risk Perceptions and Beliefs about Safer Sexual Behaviors after Human Papillomavirus Vaccination.. AIDS Behav. 22(6):1826-1834.
Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.  2012.  Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.. J Acquir Immune Defic Syndr. 61(3):390-9.
Kapogiannis BG, Leister E, Siberry GK, Van Dyke RB, Rudy B, Flynn P, Williams PL.  2016.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.. AIDS. 30(6):889-98.
Kapogiannis BG, Koenig LJ, Xu J, Mayer KH, Loeb J, Greenberg L, Monte D, Banks-Shields M, J Fortenberry D.  2020.  The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative.. J Acquir Immune Defic Syndr. 84(1):92-100.
Keizur EM, Goldbeck C, Vavala G, Romero-Espinoza A, Ocasio M, Fournier J, Lee S-J, Abdalian S-E, Rotheram MJane, Klausner JD.  2020.  Safety and Effectiveness of Same-Day Chlamydia trachomatis and Neisseria gonorrhoeae Screening and Treatment Among Gay, Bisexual, Transgender, and Homeless Youth in Los Angeles, California, and New Orleans, Louisiana.. Sex Transm Dis. 47(1):19-23.
Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW.  2019.  Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy.. AIDS Res Hum Retroviruses. 35(8):746-754.
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
L
Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, J Fortenberry D, Monte D, Tanney MR, McFarland EJ, Xu J et al..  2018.  HIV Continuum of Care for Youth in the United States.. J Acquir Immune Defic Syndr. 77(1):110-117.
Lally M, Goldsworthy R, Sarr M, Kahn J, Brown L, Peralta L, Zimet G.  2014.  Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials.. J Adolesc Health. 55(2):254-9.
Lee S, Yamazaki M, D Harris R, Harper GW, Ellen J.  2015.  Social Support and Human Immunodeficiency Virus-Status Disclosure to Friends and Family: Implications for Human Immunodeficiency Virus-Positive Youth.. J Adolesc Health. 57(1):73-80.
Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SEllen, Hoffman D, Wilson CM et al..  2013.  Comprehension of a simplified assent form in a vaccine trial for adolescents.. J Med Ethics. 39(6):410-2.
Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM et al..  2009.  Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth.. Hum Genet. 126(5):685-96.
M
Mabragaña M, Carballo-Diéguez A, Giguere R.  2013.  Young women's experience with using videoconferencing for the assessment of sexual behavior and microbicide use.. Telemed J E Health. 19(11):866-71.
MacDonell KKolmodin, Jacques-Tiura AJ, Naar S, Fernandez MIsabella.  2016.  Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.. J Pediatr Psychol. 41(4):419-28.
MacDonell K, Naar-King S, Huszti H, Belzer M.  2013.  Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV.. AIDS Behav. 17(1):86-93.
Macdonell KE, Naar-King S, Murphy DA, Parsons JT, Harper GW.  2010.  Predictors of medication adherence in high risk youth of color living with HIV.. J Pediatr Psychol. 35(6):593-601.
Martinez J, Lemos D, Hosek S.  2012.  Stressors and sources of support: the perceptions and experiences of newly diagnosed Latino youth living with HIV.. AIDS Patient Care STDS. 26(5):281-90.
Martinez J, Harper G, Carleton RA, Hosek S, Bojan K, Clum G, Glum G, Ellen J.  2012.  The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care.. AIDS Patient Care STDS. 26(2):108-15.
Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K.  2010.  Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.. Vaccine. 28(21):3672-8.
Miller RLin, Strzyzykowski T, Lee K-S, Chiaramonte D, Acevedo-Polakovich I, Spring H, Santiago-Rivera O, Boyer CB, Ellen JM.  2018.  Structural Effects on HIV Risk Among Youth: A Multi-level Analysis.. AIDS Behav. 22(11):3451-3467.

Pages